ArticleNeuroradiology2026
Automatic choroid plexus assessment in SLE: a deep learning-enabled study.
Article in Neuroradiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeThis study developed a deep learning model for automated choroid plexus (ChP) segmentation and examined its relationship with systemic inflammation and processing speed and attention deficits (PSAD) in SLE patients without major neuropsychiatric syndromes.
methodsIn this multicenter retrospective study, 137 SLE patients without major neuropsychiatric syndromes and 159 healthy controls (HCs) were enrolled. The Swin-UNETR model was trained for ChP segmentation on 3D T1-weighted MR images. SLE patients were classified as with processing speed and attention deficits (SLE-PSAD, n = 43) or intact processing speed and attention (SLE-IPSA, n = 94). Clinical, laboratory, and imaging data were compared among groups. Correlation, mediation, and LASSO regression analyses were performed.
resultsSwin-UNETR achieved high segmentation accuracy (median DSC = 0.89 internal, 0.82 external, P < 0.001). ChP volume was significantly greater in SLE-PSAD patients than in SLE-IPSA patients and HCs (P < 0.001) and positively correlated with systemic inflammation index (SII, r = 0.34, P < 0.001). Bayesian logistic regression identified increased ChP volume (aOR = 2.57), elevated SII (aOR = 2.47), and low complement component 3 (C3, aOR = 0.47) as independent PSAD risk factors. ChP volume mediated 39.2% of the SII-PSAD relationship (P < 0.001). LASSO regression identified a minimal three-biomarker model (ChP volume + C3 + SII) with excellent discriminative ability (AUC = 0.79 training, 0.77 validation).
conclusionEnlarged ChP volume is a biomarker and mediator of PSAD in SLE patients. The Swin-UNETR model enables accurate ChP quantification, and the three-biomarker panel provides a practical tool for SLE-PSAD risk stratification.
Indexed as
Identifiers
42138734What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.